NeOnc Technologies Holdings, Inc. Common Stock (NTHI) - Net Assets
Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has net assets worth $-17.51 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.82 Million) and total liabilities ($20.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NTHI current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-17.51 Million |
| % of Total Assets | -620.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NeOnc Technologies Holdings, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore total assets of NeOnc Technologies Holdings, Inc. Common for the complete picture of this company's asset base.
Annual Net Assets for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see market value of NeOnc Technologies Holdings, Inc. Common.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-17.51 Million | -218.04% |
| 2024-12-31 | $-5.50 Million | +60.65% |
| 2023-12-31 | $-13.99 Million | -787.91% |
| 2022-12-31 | $-1.58 Million | +39.79% |
| 2021-12-31 | $-2.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeOnc Technologies Holdings, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9201249600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.20K | % |
| Other Components | $95.24 Million | % |
| Total Equity | $-17.51 Million | 100.00% |
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Globrands Group Ltd
TA:GLRS
|
$96.74 Million |
|
S.Y.PANEL Co Ltd
KQ:109610
|
$96.77 Million |
|
Klingelnberg AG
SW:KLIN
|
$96.80 Million |
|
Hankook Cosmet
KO:123690
|
$96.80 Million |
|
Hillgrove Resources Ltd
AU:HGO
|
$96.63 Million |
|
We & Win Development Co Ltd
TW:2537
|
$96.59 Million |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
$96.57 Million |
|
Cavatina Holding S.A.
WAR:CAV
|
$96.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeOnc Technologies Holdings, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -5,504,961 to -17,507,729, a change of -12,002,768.
- Net loss of 62,146,210 reduced equity.
- New share issuances of 17,157,784 increased equity.
- Other factors increased equity by 32,985,658.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.15 Million | -354.96% |
| Share Issuances | $17.16 Million | +98.0% |
| Other Changes | $32.99 Million | +188.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NeOnc Technologies Holdings, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.14 | $4.06 | x |
| 2022-12-31 | $-0.08 | $4.06 | x |
| 2023-12-31 | $-0.75 | $4.06 | x |
| 2024-12-31 | $-0.29 | $4.06 | x |
| 2025-12-31 | $-0.91 | $4.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeOnc Technologies Holdings, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -155404.38%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.11 Million |
| 2022 | 0.00% | -15233.79% | 0.03x | 0.00x | $-2.89 Million |
| 2023 | 0.00% | -21176.05% | 0.06x | 0.00x | $-13.52 Million |
| 2024 | 0.00% | -14335.50% | 0.02x | 0.00x | $-11.35 Million |
| 2025 | 0.00% | -155404.38% | 0.01x | 0.00x | $-60.40 Million |
Industry Comparison
This section compares NeOnc Technologies Holdings, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $-17.51 Million | 0.00% | N/A | $96.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more